Supporting clients with everything from preclinical to Phase III trials, the role of a Bioanalytical department is certainly one of variation and importance.

‍

‍

With services ranging from development, validation, and application of bioanalytical methods and protocols, through to the preparation of sampling manuals for clinical workplaces and onwards to the analyses of active ingredients and/or metabolites in biological samples, the lab needs coordination, experience, and leadership in equal measure.

Boasting nine modern LC/MS/MS devices with triple quadrupoles, six of which are equipped with a 2-channel HPLC system, it’s fair to say that QUINTA-ANALYTICA’s Bioanalytical department is one such world-class facility.

Headed by highly experienced Vladimír Kubeš, Quinta’s BioA department hosts a database that currently contains around 300 bioanalytical methods developed and validated in-house in accordance with GLP rules, ICH/FDA, and EMEA guidelines.

Offering a comprehensive range of services including testing of the application form of drugs to guarantee compliance with exact specifications, our Bioanalytical laboratory is here to support all analytical aspects of your clinical and pre-clinical tests.

Speak to Vladimir and his team to learn more.

‍

Additional News

  • 3 September 2026

    Quinta-Analytica Expands HPLC Fleet to Strengthen Flexibility and Capacity for Clients

    New Thermo Scientific Vanquish Core joins an HPLC fleet of around 50 systems

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.